# Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer

> **NCT05035914** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Guangzhou University of Traditional Chinese Medicine** · enrollment: 94 (estimated)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** Anlotinib Hydrochloride

## Key facts

- **NCT ID:** NCT05035914
- **Lead sponsor:** Guangzhou University of Traditional Chinese Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-09
- **Primary completion:** 2022-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2021-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05035914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05035914, "Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05035914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*